Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia

NCT05482971 is registered in ClinicalTrials.gov with PharmaEssentia as lead sponsor.

NCT NCT05482971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05482971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia
Lead sponsor
PharmaEssentia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 29, 2022
Completion date
March 31, 2027
Enrollment
91 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia